CL
Clearside Biomedical, Inc.
CLSD · NASDAQ
$1.00 -3.85% (-$0.04)
Market Cap $5.23M
P/E Ratio -
Div. Yield -
ROE 55.47%
Piotroski F-Score Weak
2/9Valuation
88 /100
Cheap P/S 1.57x
P/E N/A
EV/EBITDA N/A
Growth
4 /100
Declining Rev. growth 15.16%
Book val. growth 1.67%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 85.55%
Net margin 780.90%
Op. margin 689.76%
Quality
34 /100
Average ROIC 255.12%
ROE 55.47%
ROA 223.31%
Debt
71 /100
Low Current ratio 2.98x
Int. coverage -1.39x
Net debt/EBITDA 0.44x
Stability
3 /100
Unstable Beta 1.79x
Rev. volatility 210.51%
EPS volatility 5,142.28%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CLSD
Online
About the company
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Sector
Healthcare
Industry
Biotechnology
CEO
George Lasezkay
Employees
32
Headquarters
Alpharetta